Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
— Recorded Q4'24 consolidated revenue of KRW 1.26 trillion — Recorded FY'24 consolidated revenue of KRW 4.55 trillion — Poised for further growth with expanded capacity and new service offerings Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the fourth quarter and fiscal year 2024. https://mma.prnewswire.com/media/2395686/Samsung_Biologics_Logo.jpg […]